Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
NCT06970301Phase 1Completed
- Sponsor
- UCB
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of glovadalen (3 cohorts), sponsored by UCB. Primary endpoint: Treatment-Emergent Adverse Events up to 49 days. Started Apr 2025; status: completed.
02
Drugs
glovadalen
Beyond the preview
Go deeper on NCT06970301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970301.